Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATRXOTCMKTS:FPMIOTCMKTS:SPHSOTCMKTS:XSNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRXAdhera Therapeutics$0.00$0.00▼$0.02N/A3.99663 shsN/AFPMIFluoroPharma Medical$0.00$0.00▼$0.00N/AN/AN/AN/ASPHSSophiris Bio$0.00$0.00▼$0.05$4K1.94N/AN/AXSNXNovAccess Global$0.00$0.00$0.00▼$0.02$10K3.325,224 shs8 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRXAdhera Therapeutics0.00%0.00%0.00%0.00%-98.75%FPMIFluoroPharma Medical0.00%0.00%0.00%0.00%0.00%SPHSSophiris Bio0.00%0.00%0.00%0.00%0.00%XSNXNovAccess Global0.00%0.00%-25.00%+50.00%-97.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRXAdhera Therapeutics 0.00N/AN/AN/AFPMIFluoroPharma Medical 0.00N/AN/AN/ASPHSSophiris Bio 0.00N/AN/AN/AXSNXNovAccess Global 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRXAdhera Therapeutics-$2.11MN/A0.00N/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/A0.00N/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/A0.00N/AN/AN/AN/AN/AN/AXSNXNovAccess Global-$4.72M-$0.11N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRXAdhera TherapeuticsN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRXAdhera TherapeuticsN/AFPMIFluoroPharma MedicalN/ASPHSSophiris BioN/AXSNXNovAccess GlobalN/AInsider OwnershipCompanyInsider OwnershipATRXAdhera Therapeutics28.20%FPMIFluoroPharma Medical36.90%SPHSSophiris Bio4.50%XSNXNovAccess Global1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRXAdhera Therapeutics211.63 million8.35 millionNot OptionableFPMIFluoroPharma Medical4N/AN/ANot OptionableSPHSSophiris Bio635.55 millionN/ANot OptionableXSNXNovAccess Global244.60 million43.96 millionNot OptionableATRX, XSNX, SPHS, and FPMI HeadlinesRecent News About These CompaniesGlobal wage calculator: Compare your salaryNovember 14, 2024 | money.cnn.comNovAccess Global Inc.August 28, 2024 | wsj.comNovAccess Global Inc. (XSNX)July 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 21, 2024 | finance.yahoo.comNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | finanznachrichten.deNovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | accesswire.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | accesswire.comNovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of ShareholdersMarch 1, 2024 | accesswire.comNovAccess Global Faces Default and Uncertain Rescue DealFebruary 7, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | msn.comNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitDecember 1, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 10, 2023 | finance.yahoo.comNovaccess Global Inc XSNXNovember 2, 2023 | morningstar.comBack to the Trend? Global Debt Evolution Before and After the PandemicSeptember 14, 2023 | imf.orgNovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 29, 2023 | finanznachrichten.deNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 13, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRX, XSNX, SPHS, and FPMI Company DescriptionsAdhera Therapeutics OTCMKTS:ATRXAdhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.FluoroPharma Medical OTCMKTS:FPMIFluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.Sophiris Bio OTCMKTS:SPHSSophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.NovAccess Global OTCMKTS:XSNX$0.0003 0.00 (0.00%) As of 06/16/2025NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
